Current status and perspectives in immunotherapy for metastatic melanoma

Riccardo Marconcini; Francesco Spagnolo; Luigia Stefania Stucci; Simone Ribero; Elena Marra; Francesco De Rosa; Virginia Picasso; Lorenza Di Guardo; Carolina Cimminiello; Stefano Cavalieri; Laura Orgiano; Enrica Tanda; Laura Spano; Alfredo Falcone; Paola Queirolo for the Italian Melanoma Intergroup (IMI)

doi:10.18632/oncotarget.23746

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Reviews:

Current status and perspectives in immunotherapy for metastatic melanoma

Riccardo Marconcini _, Francesco Spagnolo, Luigia Stefania Stucci, Simone Ribero, Elena Marra, Francesco De Rosa, Virginia Picasso, Lorenza Di Guardo, Carolina Cimminiello, Stefano Cavalieri, Laura Orgiano, Enrica Tanda, Laura Spano, Alfredo Falcone and Paola Queirolo for the Italian Melanoma Intergroup (IMI)

PDF | HTML | How to cite

Oncotarget. 2018; 9:12452-12470. https://doi.org/10.18632/oncotarget.23746

Metrics: PDF 3331 views | HTML 4184 views | ?

Abstract

Riccardo Marconcini1, Francesco Spagnolo2, Luigia Stefania Stucci3, Simone Ribero4, Elena Marra4, Francesco De Rosa5, Virginia Picasso2, Lorenza Di Guardo6, Carolina Cimminiello6, Stefano Cavalieri6, Laura Orgiano7, Enrica Tanda2, Laura Spano2, Alfredo Falcone1 and Paola Queirolo2 for the Italian Melanoma Intergroup (IMI)

1Unit of Medical Oncology 2, Azienda Ospedaliera-Universitaria Pisana, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Italy

2Department of Medical Oncology, IRCCS AOU San Martino-Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

3Medical Oncology Unit, Department of Biomedical Sciences and Clinical Oncology, University of Bari, Bari, Italy

4Dermatologic Clinic, Department of Medical Sciences, University of Turin, Turin, Italy

5Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST IRCCS, Meldola, Italy

6Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

7AOU Cagliari, Department of Medical Oncology, University of Cagliari, Cagliari, Italy

Correspondence to:

Riccardo Marconcini, email: [email protected]

Keywords: melanoma; immunotherapy; ipilimumab; pembrolizumab; nivolumab

Received: April 23, 2017 Accepted: November 03, 2017 Published: January 03, 2018

ABSTRACT

Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in the clinical scenario. To provide a comprehensive overview of immune modulating drugs currently available in the treatment of melanoma as well as to discuss of possible future strategies in the metastatic melanoma setting, the present review aims at analyzing controversial aspects about the optimal immunomodulating treatment sequences, the search for biomarkers of efficacy of immunocheckpoint inhibitors, and innovative combinations of drugs currently under investigation.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23746

Publication Alerts

Reviews:

Current status and perspectives in immunotherapy for metastatic melanoma

Abstract